Prominent life science developer, ProBiotix Health (a subsidiary of OptiBiotix Health plc), has entered into an exclusive deal with Inscobee for the distribution of CholBiome® in the Asia Pacific region.
ProBiotix is a leading developer of scientifically backed probiotic products that improve cardiovascular health utilising the microbiome-liver axis, while Inscobee, a public company on the Korean stock market (KOSPI) with a group turnover valued at $52.2m, is focused on expanding the bio-tech, nutraceutical and health supplement area of their business.
Over the past decade, there has been an increase in chronic diseases in Korea, with a notable rise in cardiovascular diseases (CVDs). CVDs have become one of the leading causes of morbidity and mortality in Korea and in fact are the second most common cause of mortality in the country.1
Inscobee sells and promotes nutraceuticals through hospitals and a consumer distribution base through Korean off-line channels such as Holland & Barrett stores, hypermarkets, home-shopping, and e-commerce channels including on-line malls, open markets, influencer markets and live commerce markets.
Seung-Hyeon Nam, Director of Inscobee says the company was very pleased to introduce CholBiome® products to the Korean healthcare market. “We believe CholBiome has great potential to fill the void of safe and beneficial cardiovascular health needs in the nation. We expect that it will play a big role as a flagship product of Inscobee’s healthcare business and look forward to a long and successful partnership with ProBiotix Health.”
Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health, said the agreement is another milestone in a series of deals in the Asia market, which help build LPLDL® and CholBiome’s reputation and brand awareness in the region. “Inscobee is the ideal partner in the fast moving, highly dynamic and competitive South Korean health food markets and gives us the ability to offer consumers innovative and effective natural solutions which stand out in the market.
“By entering deals for CholBiome® and LPLDL® in India, China, Malaysia, Singapore, Indonesia, Philippines, Taiwan, Australia, and New Zealand, ProBiotix is growing sales and developing a brand presence in these strategically important Asian growth markets,” he concluded.
Find out more about OptiBiotix here: https://optibiotix.com/
For more client news, visit: www.phdmarketing.co.uk/category/news/client-news/